RossiMGiorgiG. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5(3):257-262.
2.
JohannesCBVaras-LorenzoCMcQuayLJMidkiffKDFifeD. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881-888.
3.
van NoordCDielemanJPvan HerpenG. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003-1014.
GrzeskowiakLELimSWThomasAE. Audit of domperidone use as a galactogogue at an Australian tertiary teaching hospital. J Hum Lact. 2013;29(1):32-37.
6.
OsadchyAMorettiMEKorenG. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Int. 2012;2012:642893. doi:10.1155/2012/642893.
7.
HauckFRThompsonJMTanabeKO. Breastfeeding and reduced risk of sudden infant death syndrome: a meta-analysis. Pediatrics. 2011;128(1):103-110.
8.
BartickMReinholdA. The burden of suboptimal breastfeeding in the United States: a pediatric cost analysis. Pediatrics. 2010;125(5):e1048-e1056.
9.
StuebeASchwarzE. The risks and benefits of infant feeding practices for women and their children. J Perinatol. 2009;30(3):155-162.
10.
DoggrellSAHancoxJC. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf. 2014;13(1):131-138.